[2Pm] Neurodegenerative Disorders

[2Pm-105] Sustained therapeutic benefits by transient reduction of TDP-43 using ENA-modified antisense oligonucleotides in ALS/FTD mice

○Toshihide Takeuchi^1,3, Kazuhiro Maeta³, Xin Ding^2,3, Yukako Oe³, Akiko Takeda^2,3, Mana Inoue², Seiichi Nagano³, Tsuyoshi Fujihara⁴, Seiji Matsuda⁴, Shinsuke Ishigaki⁵, Kentaro Sahashi⁵, Eiko Minakawa⁶, Hideki Mochizuki³, Masahiro Neya⁴, Gen Sobue⁵, Yoshitaka Nagai^1,2,3 (1. LSRI, Kindai University, 2. Kindai University Faculty of Medicine, 3. Osaka University Graduate School of Medicine, 4. KNC Laboratories Co., Ltd., 5. Nagoya University Graduate School of Medicine, 6. NCNP)

Keywords:TDP-43, ALS, Antisense oligonucleotide, Therapy